Bank of New York Mellon Corp Acquires 6,226 Shares of Annexon, Inc. (NASDAQ:ANNX)

Bank of New York Mellon Corp boosted its holdings in Annexon, Inc. (NASDAQ:ANNX) by 2.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 230,546 shares of the company’s stock after acquiring an additional 6,226 shares during the period. Bank of New York Mellon Corp owned 0.22% of Annexon worth $1,183,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the business. China Universal Asset Management Co. Ltd. bought a new stake in Annexon in the 4th quarter valued at $116,000. Quarry LP acquired a new stake in shares of Annexon during the third quarter worth $118,000. Intech Investment Management LLC acquired a new stake in shares of Annexon during the third quarter worth $154,000. New York State Common Retirement Fund boosted its position in shares of Annexon by 143.4% in the fourth quarter. New York State Common Retirement Fund now owns 34,479 shares of the company’s stock valued at $177,000 after acquiring an additional 20,311 shares during the period. Finally, GSA Capital Partners LLP grew its stake in shares of Annexon by 10.7% in the third quarter. GSA Capital Partners LLP now owns 34,581 shares of the company’s stock valued at $205,000 after acquiring an additional 3,355 shares in the last quarter.

Annexon Stock Up 12.5 %

ANNX opened at $2.70 on Tuesday. Annexon, Inc. has a twelve month low of $2.30 and a twelve month high of $8.40. The stock has a market capitalization of $296.22 million, a price-to-earnings ratio of -2.57 and a beta of 1.14. The company has a 50-day simple moving average of $3.20 and a 200 day simple moving average of $5.08.

Annexon (NASDAQ:ANNX) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.28) by ($0.05). Sell-side analysts anticipate that Annexon, Inc. will post -0.96 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on ANNX. HC Wainwright reiterated a “buy” rating and issued a $30.00 price objective on shares of Annexon in a research note on Tuesday, December 17th. Needham & Company LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Annexon in a research report on Tuesday, March 4th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and a consensus target price of $15.80.

Annexon Profile

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.